Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Data on cancer described by F. Serana et al
June 10th, 2009
"Assessment of T-cell diversity, besides giving insights about the molecular basis of tumor antigen recognition, has clinical implications since it provides criteria for evaluating antigen-specific T cells clinically relevant for spontaneous and vaccine-induced anti-tumor activity. Melan-A is one of the melanoma antigens most frequently recognized by peripheral and tumor-infiltrating lymphocytes in HLA-A2+ melanoma patients," scientists in Brescia, Italy report. "Many clinical trials involving anti-tumor vaccination have been conducted using modified versions of this peptide. We conducted an in-depth characterization of 210 T-cell receptor beta chain (TRB) clonotypes...
Source: Vaccine Weekly (2009-06-10)
|
